Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris

Pharvaris (NASDAQ:PHVS - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Pharvaris in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($2.87) for the year, down from their prior forecast of ($2.34). The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share.

Pharvaris Price Performance

Shares of PHVS traded up $0.42 during mid-day trading on Wednesday, reaching $19.54. The company's stock had a trading volume of 55,337 shares, compared to its average volume of 53,223. Pharvaris has a 12-month low of $15.21 and a 12-month high of $33.00. The stock has a market cap of $1.02 billion, a PE ratio of -6.98 and a beta of -3.06. The company's 50 day moving average is $19.41 and its 200 day moving average is $19.35.

Hedge Funds Weigh In On Pharvaris

Several hedge funds have recently added to or reduced their stakes in PHVS. Deerfield Management Company L.P. Series C boosted its holdings in shares of Pharvaris by 31.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company's stock valued at $26,269,000 after buying an additional 335,687 shares in the last quarter. Novo Holdings A S boosted its stake in Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company's stock valued at $32,430,000 after acquiring an additional 556,970 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pharvaris during the third quarter worth about $906,000. HighVista Strategies LLC increased its position in shares of Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock worth $422,000 after purchasing an additional 6,018 shares in the last quarter. Finally, Patient Square Capital LP purchased a new stake in shares of Pharvaris in the 3rd quarter valued at about $4,488,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.